THE THIRD NATIONAL AIDS MALIGNANCY CONFERENCE
Natcher Conference Center, National Institutes of Health, Bethesda, Maryland
May 26-27, 1999
Program

May 26

8:00 AM - 8:00 PM POSTER PRESENTATIONS
First Floor Concourse, (Abstract Numbers 22 to 71)

PLENARY LECTURES
Moderators: Dr. Ellen Feigal, National Cancer Institute
Dr. Elliot Kieff, Harvard University

8:30 AM Opening Remarks and Welcome
Dr. Richard Klausner, National Cancer Institute

8:45 AM S1 Viral Oncogenesis
Dr. Harald zur Hausen, Deutsches Krebsforschungszentrum, Germany

9:10 AM S2 Angiogenesis
Dr. Isaiah J. Fidler, MD Anderson Cancer Center

9:35 AM S3 AIDS Malignancies: Innovative Approaches to Therapy
Dr. James M. Pluda, National Cancer Institute

10:00 AM Break

10:15 AM - 12:15 PM ABSTRACT PRESENTATIONS AIDS Malignancies: Epidemiology and Immunology
Moderators: Dr. Ashlee V. Moses, Oregon Health Sciences University
Dr. Patrick Moore, Columbia University
Dr. Thomas O’Brien, National Cancer Institute
Dr. Robert Newton, Imperial Cancer Research Fund, United Kingdom

10:15 AM 1 HIV and Cancer in Adults and Children in Kampala, Uganda
Dr. Robert Newton, Imperial Cancer Research Fund, United Kingdom

10:30 AM 2 Kaposi's Sarcoma: Commonest Childhood Malignancy in Zimbabwe
Dr. Inam Chitsike, University of Zimbabwe, Zimbabwe

10:45 AM 3 Risk of KS and Other AIDS Defining Diseases in HIV-HHV-8 Coinfected Individuals
Dr. Giovanni Rezza, Instituto Superiore di Sanità, Italy

11:00 AM 4 An Improved Approach for the Calibration of a New Enzyme Immunoassay for Human Herpesvirus 8 Antibodies
Dr. Jeffrey Martin, University of California, San Francisco

11:15 AM 5 HHV-8 Cellular Immune Responses in Homosexual Men
Dr. Howard D. Strickler, Albert Einstein College of Medicine

11:30 AM 6 Identification of a HLA-A 0201 Restricted, Optimal CTL Epitope in the KSHV Kaposin Protein
Dr. Christian Brander, AIDS Research Center, Massachusetts General Hospital

11:45 AM 7 Identification of HHV-8 Specific Cytotoxic T Cell Responses
Dr. Robin A. Weiss, University College London, United Kingdom
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>12 NOON</td>
<td>MHC Class I Restricted CD8+ Cytotoxic T Lymphocyte Responses to Lytic Proteins of Human Herpesvirus 8</td>
<td>Dr. Charles R. Rinaldo, Jr.</td>
<td>University of Pittsburgh</td>
</tr>
<tr>
<td>12:15 PM</td>
<td>Lunch Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PLENARY LECTURES</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:15 PM</td>
<td>S4 Virus Interactions With Immune System</td>
<td>Dr. Hidde Ploegh</td>
<td>Harvard Medical School</td>
</tr>
<tr>
<td>1:40 PM</td>
<td>S5 Cell Cycle Control by Human Papillomavirus</td>
<td>Dr. Denise Galloway</td>
<td>Fred Hutchinson Cancer Research Center</td>
</tr>
<tr>
<td>2:05 PM</td>
<td>S6 Human Papillomavirus: Cellular Immunology and Viral Vaccines</td>
<td>Dr. John T. Schiller</td>
<td>National Cancer Institute</td>
</tr>
<tr>
<td>2:30 PM</td>
<td>Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:45 PM</td>
<td>ABSTRACT PRESENTATIONS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:45 PM</td>
<td>9 Malignancy Potential of Small Ruminant Lentiviruses as Analogs to AIDS</td>
<td>Dr. Kalman Perk</td>
<td>Hebrew University of Jerusalem, Israel</td>
</tr>
<tr>
<td>3:00 PM</td>
<td>10 Regulation of Apoptosis by Viruses and Zinc Chelators Antiviral Agents: Implications for Prevention and Therapy of Viral Diseases and Cancer</td>
<td>Dr. J. Albert Fernandez-Pol</td>
<td>St. Louis University School of Medicine</td>
</tr>
<tr>
<td>3:15 PM</td>
<td>11 Clinical and Virological Features of HPV-associated Genital Lesions in HIV-infected Women</td>
<td>Dr. Annarosa Del Mistro</td>
<td>Azienda Ospedaliera di Padova, Italy</td>
</tr>
<tr>
<td>3:30 PM</td>
<td>12 Prevalence and Risks for Cervical Human Papillomavirus Infection and Squamous Intraepithelial Lesions in Adolescent Women: Impact of Infection With HIV</td>
<td>Dr. Anna-Barbara Moscicki</td>
<td>University of California, San Francisco</td>
</tr>
<tr>
<td>3:45 PM</td>
<td>13 The Effect of HAART on the Natural History of Anal Squamous Intraepithelial Lesions in HIV+ Men</td>
<td>Dr. Joel M. Palefsky</td>
<td>University of California, San Francisco</td>
</tr>
<tr>
<td>4:00 PM</td>
<td>14 The Effect of Excisional Therapy and Highly Active Antiretroviral Therapy on Cervical Intraepithelial Neoplasia in HIV Infected Women</td>
<td>Dr. William R. Robinson</td>
<td>Tulane University School of Medicine</td>
</tr>
<tr>
<td>4:15 PM</td>
<td>Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:25 PM</td>
<td>PLENARY LECTURE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:25 PM</td>
<td>S7 State-of-the-Art: Human Herpes Virus 8</td>
<td>Dr. Donald Ganem</td>
<td>University of California, San Francisco</td>
</tr>
</tbody>
</table>
4:50 PM - 6:35 PM  **ABSTRACT PRESENTATIONS  Human Herpesvirus 8**

Moderators: Dr. Ethel Cesarman, *Cornell Medical College*
Dr. Robin Weiss, *University College London, United Kingdom*
Dr. Ashlee V. Moses, *Oregon Health Sciences University*

4:50 PM  15 Cellular Tropism and Levels of Viral Gene Expression Distinguish HHV-8 Involvement in Kaposi’s Sarcoma, Primary Effusion Lymphoma and Multicentric Castleman’s Disease  
Dr. Katherine Staskus, *University of Minnesota*

5:05 PM  16 Identification and Characterization of the Two Promoter Elements of the Open Reading Frame 50 of Kaposi's Sarcoma-Associated Herpesvirus  
Dr. Shuhong Liu, *University of Nebraska-Lincoln*

5:20 PM  17 Post-transcriptional Regulation of KSHV G Protein-coupled Receptor  
Dr. Elizabeth Geras-Raaka, *Weill Medical College of Cornell University*

5:35 PM  18 The KSHV/HHV-8 G Protein-coupled Receptor Transforms Cells Through Inflammatory-Cytokine Signaling Pathways  
Dr. Lic Carlos Bais, *Cornell Medical College*

5:50 PM  19 KSHV/HHV-8 Viral MIP-II and RNA Expression in Microvascular Endothelial Cells  
Dr. David J. Looney, *University of California, San Diego*

6:05 PM  20 V-Cyclin Escapes Ubiquiton-mediated Degradation  
Dr. Philip J. Browning, *Vanderbilt University*

6:20 PM  21 The Latency-associated Nuclear Antigen Mediates Efficient Persistence of Extrachromosomal KSHV DNA  
Dr. Kenneth M. Kaye, *Harvard Medical School*

6:35 PM - 7:00 PM  Authors at poster

6:35 PM - 7:30 PM  RECEPTION, First Floor Concourse

---

**May 27**

8:00 AM - 7:30 PM  **POSTER PRESENTATIONS**  
First Floor Concourse, (Abstract Numbers 94 to 124)

---

**PLENARY LECTURE**

Moderator: Dr. Parkash Gill, *University of Southern California School of Medicine*

8:30 AM  Kaposi’s Sarcoma: Where Do We Go From Here?  
Dr. Robert Gallo, *Institute of Human Virology*

8:55 AM - 10:40 AM  **ABSTRACT PRESENTATIONS  Preclinical Model/Clinical Implications**

Moderators: Dr. Robert Gallo, *Institute of Human Virology*
Dr. Parkash Gill, *University of Southern California School of Medicine*

8:55 AM  72 The Distribution of HHV-8 Latently Infected Cells in All Stages of Kaposi's Sarcoma  
Dr. Robin A. Weiss, *University College London, United Kingdom*

9:10 AM  73 *In Vitro* Infection of Primary Human Keratinocytes by Kaposi's Sarcoma Associated Herpesvirus  
Dr. Francesca Cerimele, *Weill Medical College of Cornell University*
9:25 AM 74 Creation of Kaposi's Sarcoma (KS)-like Lesions Using HHV-8 Injected Into Engrafted Human Skin on SCID Mice
Dr. Kimberly Foreman, Loyola University

9:40 AM 75 HHV-8/KSHV Infects Dermal Endothelial Cells and Macrophages: Implications for Kaposi's Sarcoma
Dr. Ashlee V. Moses, Oregon Health Sciences University

9:55 AM 76 *In Vitro* Inhibition of KSHV/HHV-8 Infected Endothelial Cell Growth by Neutralizing Monoclonal Antibodies to Human VEGFR-2
Sarah Nikolovska, Weill Medical College of Cornell University

10:10 AM 77 RNA Damage and Inhibition of Kaposi's Sarcoma Cell Growth: Effects of Human vs Amphibian Ribonucleases
Dr. Dianne L. Newton, National Cancer Institute

10:25 AM 78 Administration of Interleukin 12 to Patients With AIDS-associated Kaposi's Sarcoma: Preliminary Results of a Pilot Study
Dr. James M. Pluda, National Cancer Institute

10:40 AM Break

**PLENARY LECTURES**

Moderator: Dr. Elaine S. Jaffe, National Cancer Institute

10:55 AM S8 Immune Control in Neoplasia
Dr. Drew M. Pardoll, Johns Hopkins University

11:20 AM S9 Post-transplant Lymphoproliferative Disease and Implications for AIDS Malignancies
Dr. Lode J. Swinnen, Loyola University

11:45 AM Lunch Break

12:45 PM - 2:15 PM **ABSTRACT PRESENTATIONS** Lymphomas and Other Neoplasia: Pathogenesis

Moderators: Dr. Peter Biberfeld, Karolinska Institute, Sweden
Dr. Gianluca Gaidano, “Amedeo Avogadro” University of Eastern Piedmont

12:45 PM 79 An Increased Risk of B-cell Lymphomas in Autoimmune Lymphoproliferative Syndrome
Dr. Elaine S. Jaffe, National Cancer Institute

1:00 PM 80 A Histogenic Model for Hodgkin's Disease Development in HIV-Positive and HIV-Negative Individuals
Dr. Antonino Carbone, Centro di Riferimento Oncologico, Italy

1:15 PM 81 Sequential Pathogenesis: A Model Implicating a Role for Clonal Macrophages in Neoplastic and Degenerative HIV Associated Diseases
Dr. Michael S. McGrath, University of California, San Francisco

1:30 PM 82 Novel Integration Sites in Pediatric Malignancies
Dr. Bruce Shiramizu, University of Hawaii

1:45 PM 83 Role of Epstein-Barr Virus in the Development of AIDS-related Non-Hodgkin's Lymphoma
Debbie van Baarle, Sanquin Blood Supply Foundation, The Netherlands

2:00 PM 84 Expression of Epstein Barr Virus Genes in Post-Transplant Lymphoproliferative Disorders
Dr. Elizabeth Hyjek, Weill Medical College of Cornell University
PLENARY LECTURE
Moderator: Dr. David T. Scadden, Harvard Medical School

2:15 PM S10 Animal Models: Immunodeficiency and Neoplasia
Dr. Peter Biberfeld, Karolinska Institute, Sweden

2:40 PM Break

PLENARY LECTURE
Moderator: Dr. David T. Scadden, Harvard Medical School

2:55 PM Role of the National Cancer Institute in AIDS-related Drug Discovery
Dr. Edward Sausville, National Cancer Institute

3:20 PM - 5:35 PM ABSTRACT PRESENTATIONS  Lymphomas: Preclinical Models and Clinical Aspects
Moderators: Dr. Umberto Tirelli, Centro di Riferimento Oncologico, Italy
Dr. Peter Biberfeld, Karolinska Institute, Sweden

3:20 PM 85 Molecular Profile of Epstein-Barr Virus Infection in AIDS-Related Primary Central Nervous System Lymphoma
Dr. Lucia Fassone, “Amedeo Avogadro” University of Eastern Piedmont

3:35 PM 86 Combination Antiviral Therapy for Treatment of Primary Central Nervous System Lymphoma Associated With the Epstein Barr Virus: In Vivo Evaluation in an Animal Model
Dr. Michael A. Caligiuri, Ohio State University

3:50 PM 87 Antivirals Induce Apoptosis and Tumor Regression in AIDS-related Primary Central Nervous System Lymphoma
Dr. William J. Harrington Jr., University of Miami School of Medicine

4:05 PM 88 AIDS Lymphomagenesis Mouse Model
Dr. Elizabeth Zenger, University of California, San Francisco

4:20 PM 89 Pathophysiological Role of Vascular Endothelial Growth Factor/Vascular Permeability Factor in Primary Effusion Lymphomas
Dr. Yoshiyasu Aoki, United States Food and Drug Administration

4:35 PM 90 Multi-drug Resistance in Newly Diagnosed AIDS-lymphoma
Dr. Anil Tulpule, University of Southern California School of Medicine

4: 50 PM 91 Treatment of HIV-related Non-Hodgkin's Lymphoma Adapted to Prognostic Factors
Dr. Umberto Tirelli, Centro di Riferimento Oncologico, Italy

5:05 PM 92 Chemotherapy for HIV-associated Non-Hodgkin’s Lymphoma in Combination With Highly Active Antiretroviral Therapy is not Associated With Excessive Toxicity
Dr. Lee Ratner, Washington University

Dr. Richard F. Little, National Cancer Institute

5:35 PM - 6:00 PM Authors at poster

5:35 PM - 6:30 PM RECEPTION, First Floor Concourse